About this episode
In The Tox Talks we feature expert injectors with significant experience using botulinum toxins. We explore their experience with particular brands, how their techniques have evolved and the subtle nuances of getting the best out of toxins.
In Chapter 9 we discuss a new on-label indication for Botox (Allergan Aesthetics, an AbbVie company): masseter muscle prominence (MMP). It was approved in China at an event in Shanghai, making Botox the first and only toxin brand approved for this indication.
Dr Felix Li and Dr Stefania Roberts cover masseter anatomy and aesthetics, on-label versus off-label use, culture and facial ideals, how toxin changes muscle function, consultation, alternatives and surgery, study and real-world dosing by age and ethnicity, needle depth and anatomy errors, paradoxical bulging, avoiding the risorius, three-point injection mapping, preventing jowls and parotid mix-ups, and pricing and maintenance.
What you'll learn
- Why masseter muscle prominence approval matters
- Masseter anatomy and facial ideals
- Study versus real-world dosing
- Needle depth and common anatomy errors
- What causes paradoxical bulging
- Three-point injection mapping
Topics
- The Tox Talks
- Botulinum toxin
- Botox
- Masseter
- Jawline
- Allergan
- Singapore
- Australia
Full transcript
The full transcript for this episode is coming soon.